Home › Research › Drug development
New and emerging drug therapies for Alzheimer disease
Waite LM.. Australian prescriber, 2024-06-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Established drug therapies for Alzheimer disease (cholinesterase inhibitors and memantine) do not modify the disease course and provide only modest clinical benefit. Biomarker measures of amyloid, tau and neurodegeneration have been integral to Alzheimer disease clinical trials for biologic drugs, for patient selection and efficacy monitoring. At the time of writing, two monoclonal antibodies targeting the amyloid-beta protein (aducanumab and lecanemab) have been approved in the USA, and two agents (lecanemab and donanemab) are under evaluation by the Therapeutic Goods Administration in Australia.
What this study adds
Evidence grade: Low
This is a narrative review. This review states that established drug therapies for Alzheimer's disease (cholinesterase inhibitors and memantine) do not modify the disease course and provide only modest clinical benefit. It notes that two monoclonal antibodies targeting amyloid-beta (aducanumab and lecanemab) have been approved in the USA, and two agents (lecanemab and donanemab) are under evaluation in Australia.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Waite, L. M. (2024). New and emerging drug therapies for Alzheimer disease. Australian prescriber. https://doi.org/10.18773/austprescr.2024.021
Vancouver
Waite LM. New and emerging drug therapies for Alzheimer disease. Australian prescriber. 2024. doi:10.18773/austprescr.2024.021. PMID: 38962384.
BibTeX
@article{waite2024-38962384,
author = {Waite, L. M.},
title = {{New and emerging drug therapies for Alzheimer disease}},
journal = {Australian prescriber},
year = {2024},
doi = {10.18773/austprescr.2024.021},
pmid = {38962384},
url = {https://doi.org/10.18773/austprescr.2024.021}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Biomarker measures of amyloid, tau and neurodegeneration have been integral to Alzheimer disease clinical trials for biologic drugs, for patient selection and efficacy monitoring.
- At the time of writing, two monoclonal antibodies targeting the amyloid-beta protein (aducanumab and lecanemab) have been approved in the USA, and two agents (lecanemab and donanemab) are under evaluation by the Therapeutic Goods Administration in Australia.
- Clinical trials have demonstrated that monoclonal antibodies are effective at removing amyloid from the brain in people with early Alzheimer disease.
- Cognitive benefits are statistically significant, but do not achieve the minimal clinically important difference.
Why it matters
This review states that established drug therapies for Alzheimer's disease (cholinesterase inhibitors and memantine) do not modify the disease course and provide only modest clinical benefit. It notes that two monoclonal antibodies targeting amyloid-beta (aducanumab and lecanemab) have been approved in the USA, and two agents (lecanemab and donanemab) are under evaluation in Australia.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Australian prescriber) |
| Journal's citation record | 0 / 4 | Australian Prescriber: journal h-index 61 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 20 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 3 / 6 | Cited 4.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Louise M. Waite: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Sydney: institution h-index 1,466 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38962384) |
| Free to read | 2 / 2 | Free to read |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.18773/austprescr.2024.021
- PubMed: 38962384
- Original source →
- Free full text: Australian Prescriber →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Drug development from nearby years
Also in Drug development
117 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.